A multicenter, randomized, double-blind study to determine the efficacy and safety of the addition of SYR-322 25 mg versus dose titration from 30 mg to 45 mg of pioglitazone HCl (ACTOS) in subjects with type 2 diabetes mellitus who have inadequate control on a combination of metformin and 30 mg of pioglitazone HCl therapy.

Trial Profile

A multicenter, randomized, double-blind study to determine the efficacy and safety of the addition of SYR-322 25 mg versus dose titration from 30 mg to 45 mg of pioglitazone HCl (ACTOS) in subjects with type 2 diabetes mellitus who have inadequate control on a combination of metformin and 30 mg of pioglitazone HCl therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Alogliptin (Primary) ; Metformin; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Jun 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 01 Dec 2011 Results published in the Diabetes, Obesity and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top